New Antimalarial Drug Leads Targeting Multiple Species And Life Cycle Stages
Funder
National Health and Medical Research Council
Funding Amount
$818,477.00
Summary
Malaria causes ~200 million clinical cases and >430,000 deaths annually. Prevention and treatment relies on drugs, however malaria parasite drug resistance is an enormous problem. To address this issue, and aim towards eliminating malaria, we need to develop new drugs. This project addresses this important health need by investigating the ability of new chemical compounds, developed at CSIRO, to kill human-infecting malaria parasites during different parts of their complicated lifecycles.
Biogenesis of the relict plastid of Apicomplexan parasites: the role of a dynamin-related protein in apicoplast division. The Apicomplexa are a group of intracellular parasites that cause several important diseases. Most Apicomplexa contain an organelle called the apicoplast that is indispensable for their survival and that can only form through the division of pre-existing apicoplasts. This project will examine the molecular mechanisms of how this process occurs.
Cytosolic And Organellar TRNA Synthetases In Plasmodium Falciparum
Funder
National Health and Medical Research Council
Funding Amount
$424,262.00
Summary
Malaria is a major worldwide infectious disease. The disease kills around 2 million people every year, and current drugs are increasingly failing due to parasite drug resistance, creating an urgent demand for new drugs, that inhibit different targets. I will study a new class of parasite drug targets, the tRNA synthetase enzymes to find novel inhibitors. Compounds blocking these enzymes may lead to new drugs to combat malaria.
In 2013 there were ~200 million clinical cases of malaria, causing ~600,000 deaths. All antimalarial drugs are now associated with malaria parasite resistance. Thus, new therapies are urgently needed, including new drugs to prevent this disease. We have made the exciting discovery that an existing antimalarial drug can kill malaria parasites in a unique, previously unknown, manner. Here, we will investigate how this occurs and develop new drug candidates for malaria prevention.
Special Research Initiatives - Grant ID: SR140200003
Funder
Australian Research Council
Funding Amount
$42,000,000.00
Summary
Australian Institute of Tropical Health and Medicine. AITHM intends to build Australian research capacity in tropical health and biomedical sciences, to improve national capacity to identify risks to health security and biosecurity from re-emerging infectious diseases prevalent in tropical countries, and to undertake research which targets improvements in health outcomes and service delivery for regional, remote, and under-served communities in tropical Australia. This requires expansion of trop ....Australian Institute of Tropical Health and Medicine. AITHM intends to build Australian research capacity in tropical health and biomedical sciences, to improve national capacity to identify risks to health security and biosecurity from re-emerging infectious diseases prevalent in tropical countries, and to undertake research which targets improvements in health outcomes and service delivery for regional, remote, and under-served communities in tropical Australia. This requires expansion of tropically based research facilities, the researcher skill base, and research programs.Read moreRead less
My research team is focused on human parasites of major relevance to the Australian water industry and/or global public health. Our primary focus is the use of advanced technologies to improve understanding of these parasites and to utilize this information to underpin development of new drugs to treat them and novel diagnostic tests to improve their control.
Transcriptional control of antigenic variation in the malaria parasite Plasmodium falciparum. Malaria is a major health concern for the Australian Defence Personnel recently deployed in East Timor, Afghanistan and the Solomon Islands and is endemic in our immediate neighbours Indonesia and Papua New Guinea. Australia is susceptible to malaria and climate change could extend the mosquitos range to large population centres of Northern Australia causing malaria in Australia. This study would clarif ....Transcriptional control of antigenic variation in the malaria parasite Plasmodium falciparum. Malaria is a major health concern for the Australian Defence Personnel recently deployed in East Timor, Afghanistan and the Solomon Islands and is endemic in our immediate neighbours Indonesia and Papua New Guinea. Australia is susceptible to malaria and climate change could extend the mosquitos range to large population centres of Northern Australia causing malaria in Australia. This study would clarify how malaria parasites evade the host's immune response and help to protect Australia by providing drug targets for the control of this invasive disease.Read moreRead less
The Control And Regulatory Mechanisms Of Artemisinin Induced Dormancy In P. Falciparum
Funder
National Health and Medical Research Council
Funding Amount
$495,552.00
Summary
Malaria is a major global health problem and can only be reliably treated with artemisinin combinations in many areas due to widespread of drug resistance. However a proportion of parasites appear to be able to avoid the lethal effects of the drug by becoming “dormant” following exposure. They resume growth after the drug is wanned, a feature which is reminisent to cell cycle arrest. This study investigates the role of cell cycle machinery in dormancy following arteminsinin treatment.
We will investigate malaria, a parasitic disease that kills over 2 million people a year. We will explore how the parasite identifies, invades and remodels the host cells in which it lives, scavenging nutrients and hiding from the immune system. We will characterize the proteins involved in these critical events, as they are potential targets for drugs and vaccines. We will study how parasites cause disease and how the host responds to infection.